Alpha-enolase is a potential prognostic marker in XXXX .

@entity1 @entity146 @entity5 @entity19992 @entity1358
UNASSIGNED: @entity1358 ( @entity1358 ) is an @entity146 with unpredictable behaviour. Clinical parameters are not always accurate for prognosis prediction. The integration of molecular markers to prognostic models can significantly improve prognostic assessment and consequently @entity1 management. We assessed the expression of alpha-enolase ( @entity19992 ) protein by immunohistochemistry in 360 @entity1 with primary @entity1358 and correlated its expression with multiple clinicopathological parameters including stage, grade, @entity5 size, disease-free and overall survival. Cox proportional hazard regression models adjusted for clinicopathological factors were used to test for a link between @entity19992 expression and both disease-free and overall survival. We correlated @entity19992 mRNA expression with overall survival in an independent set of 428 @entity1358 cases from The Cancer Genome Atlas. @entity19992 showed cytoplasmic, membranous and nuclear staining patterns. There is a  statistically significant negative correlation between @entity19992 expression, @entity5 stage, and grade. @entity19992 expression also shows a statistically significant direct correlation with disease-free survival (p  =  0.011) and overall survival (p  =  0.030) in @entity1358 . @entity1 with higher @entity19992 expression had lower hazard ratio of recurrence, although this was not statistically significant (HR  =  0.330, p  =  0.060). These findings were validated at the mRNA level in an independent set of 428 @entity1358 cases which also showed that low @entity19992 expression is associated with significantly shorter overall survival. Down-regulation of @entity19992 can be a predictor of poor prognosis in @entity1358 , and it can be a potential prognostic marker.
